JP5010079B2 - マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 - Google Patents

マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 Download PDF

Info

Publication number
JP5010079B2
JP5010079B2 JP2001509760A JP2001509760A JP5010079B2 JP 5010079 B2 JP5010079 B2 JP 5010079B2 JP 2001509760 A JP2001509760 A JP 2001509760A JP 2001509760 A JP2001509760 A JP 2001509760A JP 5010079 B2 JP5010079 B2 JP 5010079B2
Authority
JP
Japan
Prior art keywords
polypeptide
ifn
positive
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001509760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510018A (ja
JP2003510018A5 (https=
Inventor
アンデルセン，ペーター
スクジョ，リッケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of JP2003510018A publication Critical patent/JP2003510018A/ja
Publication of JP2003510018A5 publication Critical patent/JP2003510018A5/ja
Application granted granted Critical
Publication of JP5010079B2 publication Critical patent/JP5010079B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001509760A 1999-07-13 2000-07-13 マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法 Expired - Lifetime JP5010079B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK199901020 1999-07-13
DKPA199901020 1999-07-13
DKPA199901020 1999-07-13
US14401199P 1999-07-15 1999-07-15
US60/144,011 1999-07-15
PCT/DK2000/000398 WO2001004151A2 (en) 1999-07-13 2000-07-13 TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010262852A Division JP5075969B2 (ja) 1999-07-13 2010-11-25 マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法

Publications (3)

Publication Number Publication Date
JP2003510018A JP2003510018A (ja) 2003-03-18
JP2003510018A5 JP2003510018A5 (https=) 2007-08-30
JP5010079B2 true JP5010079B2 (ja) 2012-08-29

Family

ID=26065081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001509760A Expired - Lifetime JP5010079B2 (ja) 1999-07-13 2000-07-13 マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法

Country Status (6)

Country Link
US (1) US7867502B1 (https=)
EP (1) EP1200466A2 (https=)
JP (1) JP5010079B2 (https=)
AU (3) AU779495B2 (https=)
CA (1) CA2378763A1 (https=)
WO (1) WO2001004151A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291190B1 (en) * 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
ID29858A (id) * 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
AU2002219338B2 (en) 2001-01-08 2006-12-14 Oxford Immunotec Limited Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) 2002-07-05 2002-08-14 Isis Innovation Diagnostic method
WO2004099771A1 (en) * 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
US20060002941A1 (en) * 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
CN100401066C (zh) * 2005-09-23 2008-07-09 中国人民解放军第三○九医院 基于组合蛋白的结核分枝杆菌金标诊断试剂
JP5805368B2 (ja) * 2006-09-05 2015-11-04 ステイテンス・セラム・インスティテュート Ｉｐ−１０に基づく免疫学的モニタリング
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2714383T3 (es) 2009-04-24 2019-05-28 Statens Seruminstitut Vacuna TB contra la tuberculosis para impedir la reactivación
WO2011063283A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
GB201012072D0 (en) * 2010-07-19 2010-09-01 Sec Dep For Environment Food A Diagnostic reagents
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
CN102183649A (zh) * 2011-01-31 2011-09-14 中国农业大学 牛结核病抗原特异性γ-干扰素ELISA试剂盒
LT3084442T (lt) * 2013-12-16 2021-07-12 Statens Serum Institut Diagnostiniai reagentai, skirti pagerintai in vivo arba in vito ląstelių medijuojamai imunologinei tuberkuliozės diagnozei
CN103974483B (zh) * 2014-05-25 2016-03-16 上海洞舟实业有限公司 一种电感电致发光线
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CA2319380A1 (en) 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053076A2 (en) * 1997-05-20 1998-11-26 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use

Also Published As

Publication number Publication date
WO2001004151A3 (en) 2001-07-12
AU779495B2 (en) 2005-01-27
JP2003510018A (ja) 2003-03-18
EP1200466A2 (en) 2002-05-02
US7867502B1 (en) 2011-01-11
AU2008224343A1 (en) 2008-10-16
AU2008224343B2 (en) 2012-05-10
CA2378763A1 (en) 2001-01-18
AU2005201767A1 (en) 2005-05-19
WO2001004151A2 (en) 2001-01-18
AU5966400A (en) 2001-01-30
AU2005201767B2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
AU2008224343B2 (en) Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family
US8142797B2 (en) Therapeutic TB vaccine
US7037510B2 (en) Hybrids of M. tuberculosis antigens
US8076469B2 (en) TB diagnostic based on antigens from M. tuberculosis
CN102836425B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
JP4172598B2 (ja) 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
AU9433898A (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
AU2001250294A1 (en) Tuberculosis antigens and methods of use thereof
JP2003510018A5 (https=)
WO2005061534A2 (en) Improved tuberculosis vaccines
AU766093B2 (en) Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
US20040013685A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
JP5075969B2 (ja) マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
AU2012202486B2 (en) Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family
US7041295B2 (en) Compounds for treatment of infectious and immune system disorders and methods for their use
EP1484405A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
EP1787994A1 (en) TB vaccine and diagnostic based on antigens from M. tuberculosis cell
AU2011203012A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120508

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120601

R150 Certificate of patent or registration of utility model

Ref document number: 5010079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150608

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250